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Background: Conventional Cardiopulmonary Bypass (cCPB) is a trigger of systemic inflammatory reactions,
hemodilution, coagulopathy, and organ failure. Miniaturised Cardiopulmonary Bypass (mCPB) has the potential to
reduce these deleterious effects. Here, we describe our standardised ‘Hammersmith’ mCPB technique, used in all
types of adult cardiac operations including major aortic surgery.
Methods: The use of mCPB remains limited by the diversity of technologies which range from extremely complex,
micro systems to ones very similar to cCPB. Our approach is designed around the principle of balancing the
benefits of miniaturisation; reducing foreign surface area while maintaining patient safety.
Results: From January 2010 to March 2011, a single surgeon performed 184 consecutive operations (Euro score
Logistic 8.4+/−9.9): 61 aortic valve replacements, 78 CABGs, 25 aortic valve replacement and CABG and 17 other
procedures (major aortic surgery, re-do operations or double/triple valve replacements).
Our clinical experience suggests that:
i. Venous drainage is optimally maintained using kinetic energy.
ii. Venous collapse pressure depends on the patient’s anatomy and cannula size, but most importantly on the
negative pressure generated by venous drainage.
iii. The patient-prime interaction is optimised with antegrade and retrograde autologous priming, which mixes
the blood and prime away from the tissues and results in a reduced oncotic destabilization.
iv. mCPB is a safe and reproducible technique
Conclusion: The Hammersmith mCPB is a “next generation” system which uses standard commercially available
components. It aims to maintain safety margin and the benefit of miniaturised system whilst reducing the human
factor demands.
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Conventional cardiopulmonary bypass (cCPB) remains
the most common type of cardiopulmonary bypass
(CPB), with only 4-10% of operations using miniaturised
CPB (mCPB). Potential advantages of mCPB include a
reduction in the deleterious effects of CPB, patient derived
volume addition, and better physiological compatibility.
An early, small-randomized controlled trial (RCT) [1]
reported that mCPB “marginally” reduced coagulation* Correspondence: g.d.angelini@imperial.ac.uk
1Cardiac Surgery and Clinical Perfusion, Imperial College London, London, UK
2Hammersmith Hospital, Imperial College London, London, UK
© 2013 Momin et al.; licensee BioMed Central
Commons Attribution License (http://creativec
reproduction in any medium, provided the orand inflammatory markers but also expressed concern
about safety. Recently, RCTs have consistently reported
benefits of mCPB, including reductions in length of stay
in the intensive care unit, lower blood loss and transfu-
sion requirements, improved renal and neurological out-
comes [2-5], a higher mean arterial pressure during
CPB, a lower consumption of vasoactive drugs, and a re-
duced inflammatory response. A meta-analysis of 33
RCTs showed mCPB to be associated with a lower risk
of blood loss, postoperative stroke, and mortalityLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ings was limited by the diversity of mCPB technologies
evaluated in the RCTs, which ranged from extremely
complex, micro systems to ones very similar to cCPB
technology.
Some of the diversity is explained firstly by advances
in mCPB technology, which have improved the safety of
mCPB [4,7], but also the absence of an agreed definition
for the technology which allows many different systems
to be included under the miniaturized umbrella. It re-
mains a major challenge to standardise an optimal sys-
tem capable of eliciting the benefits of miniaturisation
while retaining an adequate safety margin. In this paper,
we describe our Hammersmith mCPB system initially
used by a single surgeon (JA) and now progressively
adopted by the rest of the unit surgeons.
Methods
Anaesthesia is maintained using a mixture of propofol
and remifentanil. Blood gas analysis and activated clot-
ting time (ACT) are checked regularly to maintain a
minimum ACT of 400 seconds during CPB. Patients are
cooled to 32°C. A cardiac index of 1.8 - 2.4 L/m2/min is
used to determine each patient’s target normothermic
cardiac output. Myocardial protection is achieved using
either cold (4:1 ratio) blood-cardioplegia or intermittent
cross-clamp fibrillation.
Our mCPB system (Sorin Group Italia) is built from a
set of standard components (Table 1) tailored to specific
circumstances, i.e. the patients’ characteristics, plannedTable 1 Components of the standard Hammersmith mCPB cir
Prime Volume 134 ml (w








Air interface 100 ml in




Safety features VARD *
Ramp Do
Electronic
Cell saving device Dideco El
* See Figure 1 for details; VARD Venous Air Removal Device.procedure, and the perfusionist and surgical teams ex-
perience (Figure 1).
We balance Foreign Surface Area (FSA) of the system
with clinical applicability to maintain patient safety
(Table 2). For example, we monitor and control the
negative pressure in the venous line using the patient-
specific venous collapse pressure as the threshold value.
The venous cannula we use (Figure 1a) facilitates opti-
misation in this area of our system as its design in-
creases the patient-specific venous collapse pressure.
A venous air removal device (VARD) facilitates the
management of gross and microscopic air removal,
which is a key safety advantage (Figure 1b) and provides
‘active’ microscopic air removal, rather than the ‘passive’
micro air removal achieved using a cCPB hard-shell ven-
ous reservoir. We prefer a centrifugal pump although a
standard roller pump can also be used as long as the
pump is linked to the venous line pressure (Figure 1c).
We carefully consider the size of FSA we expose the pa-
tients’ blood to, as well as the exposure time. For ex-
ample we use an oxygenator with a very high ratio of gas
exchange surface area to FSA. Manufacturers quote the
gas exchange surface area but it is important to know
how much FSA is required to achieve that gas exchange
surface area. A well design oxygenator boasting good
fluid dynamics will minimise the FSA required to pro-
vide the gas exchange surface. We use a 1.2 m2 oxygen-
ator which provides a 1.1 m2 gas exchange surface
(Figure 1d). The advantages of using a smaller 1.1 m2
gas exchange surface have to be balanced againstcuit
ith ante grade and retrograde priming)
or – 1.1 m2 *
.0105 m2 *
Bag 0.0860 m2 *or Midi Card – 0.0535 m2 *
301 m2 (1.268 m2)
0.0747 m2
e Filter – 0.0300 m2 (D733, Low Prime Sorin group)
s Filter (0.5 μm filter within the arterial-venous sash (Siever, [Sorin group])
al and Venous lines
Midi Card – 8.14 × 10-4 m2 *
nting as standard
vinylchloride lines to act as an aortic root and Left Ventricular
soft shell bag
us communication with surgeon
wn function
clamp
ectra [Sorin group, Italy]
Figure 1 Schematic and flowchart of the Hammersmith mCPB system. (a) 29-French OptiFlow venous cannula (Sorin Group, Mirandola,
Italy); (b) venous air removal device; (c) centrifugal pump (Revolution Cardiopulmonary Bypass; Stöckert, Munchen, Germany); (d) heat exchange,
and oxygenator module (Eos [Sorin Group, Mirandola, Italy]); (e) arterial line filter; and (f) parallel soft-shell reservoir.
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capacity of the oxygenator that is not used. In our ex-
perience, the margin remains acceptable even at normo-
thermic levels where we would comfortably run FiO2’s
at 75% (25% FoS) rather than at 65% (35%FoS). Versatil-
ity is enhanced by allowing for an optional isolated soft-
shell reservoir (SSR) or Midi card running in parallel to
the systemic circulation (Figure 1f and Table 3). This op-
tion facilitates management of circulating volume in
high-risk circumstances, although at the expense of in-
creased FSA.
MCPB requires the patient to be used as a reservoir.
Consequently, it can pose challenges, such as the need
to reposition the operating table to facilitate venous
drainage and filling. The use of a SSR eliminates this
problem. A key feature of the SSR is its position in par-
allel, not in series as in cCPB, thus eliminating blood
FSA exposure on every pass through the system (limit-
ing exposure time). It has no air interface and the perfu-
sionist manually removes any air introduced by the vent
into the SSR. Therefore, a SSR can be routinely used in
circumstances that are unlikely to give rise to complex
air/vent management issues. For more complex circum-
stances, a hard shell reservoir (HSR), Midi Card, is used;
despite a limited air interface, the Midi Card allowseasier air management from the vent and suction be-
cause it is automated. Both of these aspects of our sys-
tem can be perceived to be a disadvantage but when
considered in context the advantages in terms of clinical
applicability outweigh any disadvantages. Take for ex-
ample the introduction of a soft-shell reservoir, clinical
applicability is significantly increased, it also presents an
additional FSA of 0.086 m2 which is insignificant com-
pared to the FSA of an Oxygenator.Results
Review of our experience using mCPB was approved by
the clinical audit committee of the Imperial College Na-
tional Health Service Trust to meet ethical and legal re-
quirements, and individual consent was waived. From
January 2010 to March 2011, a single surgeon (JA) car-
ried out 61 isolated aortic valve replacements, 78
CABGs, 25 aortic valve replacement and CABG and 17
other operations (major aortic surgery, re-do operations
or double/triple valve replacements) on 184 consecutive
patients. The mean logistic Euro score was 8.4 +/− 9.9
SD. The consultant performed 74% of operations and
surgical residents performed the remainder under
supervision.
Table 2 Advantages and disadvantages of mCPB and cCPB
mCPB cCPB
Venous cannula 29 Fr OptiFlow (Sorin) 34/46 Fr 2-stage (Medtronic)
Advantage • Multi-stage and longer length (increasing drainage
and structural support in IVC)
• Convenient and easy placement
• Less prone to collapse and blockage due to side
holes and grooves
• This type of cannulae is used in common practice
Disadvantage • Rigid (requiring careful placement) as it extends
further down the IVC
• Larger – increased risk of interaction with IVC/RA wall




3/8 inch tubing ½ inch tubing
Advantage • Smaller, active kinetic drainage • Gravity syphon based
• Monitored controlled drainage • Simple, standard and convenient
• Tailored to patient specific venous collapse pressure
Disadvantage • Uncontrollable
• Not routinely monitored
VARD Advisable to use in mCPB but not compulsory VARD is not required due to the presence of the Venous reservoir but it has been proven to be of benefit
in all CPB circuits [8]. However, it is not commonly used.
Advantage • Enhances safety • Cheaper
• Efficient gross air removal • Simple open system
• Active micro air removal • The reservoir filters and removes gross air easily
• Decreases FSA versus standard filters used in CPB
venous reservoir’s
• Continuity
• All air introduction into system
Disadvantage • Require perfusion experience • No active removal of micro-embolic air (just passive)
• Extra Component of circuit • Venous reservoir in series (continued FSA exposure)
• Vented blood has to be manually returned back
into the systemic system
• Increases FSA
Reservoir* SSR or Midi card Venous reservoir (Sorin Evo)
Advantage • Closed (no ‘in series’ blood-air interface- limits FSA
exposure)
• Open
• Decreased damage to blood cells • Common practice
• Optimises vent management • Venting possible
• Midi card ‘in parallel’ automatic air removal • Low Pressure Suction and blood venting possible
• • Vented blood is automatically returned to the systemic circulation

















Table 2 Advantages and disadvantages of mCPB and cCPB (Continued)
• No Low Pressure Suction (an issue in cases where
there are high volumes of LPS)
• Damage to blood cells
• Vented blood has to be manually returned back
into the systemic circulation
• Disguises poor suction/vent management
Centrifugal pump Revolution (Stöckert, Germany) Standard roller pump
Advantage • Non-occlusive • ½ inch silicon tubing
• Pressure regulates • Cost-effective
• Gross safety mechanism
• Less blood cell trauma
Disadvantage • Cost and training • Occlusive (No pressure regulation)
Heat exchanger and
oxygenator
Eos (Sorin Group, Italy) Avant (Sorin Group, Italy)
Advantage • 1.1 m2 (decreased) FSA • High ‘factor of safety’
• Efficient use of fibre bundle capacity • 7.5 L/min blood flow
• high ratio of gas exchange surface area to FSA
Disadvantage • Reduced (but acceptable) ‘factor of safety’ • 1.8 m2 FSA
• Excessive ‘factor of safety’ for our patient population
Arterial line filter Pall AL6 low prime Pall AL6 low prime
* We begin training junior perfusionists with Midi card and after experience is gained, we move to SSR for routine cases. With further experience both by surgical and perfusionist teams, we move forward to Soft Shell

















Table 3 mCPB: soft shell reservoir and Midi card options
Options
Soft shell reservoir Midi card
Patient All All
Operation AVR, CABG, AVR + CABG Complex operation, redo, Aortic root, Mitral,
Experienced perfusionist * Case selection
Device Parallel Yes Yes
Blood-air interface No Yes (minimal)
Vented Blood Air removal Manual (active) Automatic
Open reservoir
Independent of perfusionist
Venting Experienced management and good communication Easily managed, not labour intensive
AVR Aortic Valve Replacement, CABG Coronary Artery Bypass Graft, FSA Foreign Surface Area, IVC Inferior Vena Cava, SSR Soft shell Reservoir, VARD Venous Air
Removal Device. * We begin training junior perfusionists with Midi card and after experience is gained, we move to SSR for routine cases. With further experience
both by surgical and perfusionist teams, we move forward to Soft Shell Reservoir (SSR) for all cases regardless of complexity. The characteristics of these two
options are described below.
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conclusion:
Venous drainage is optimally maintained using kinetic
energy which provides controlled removal of fluid vol-
ume from the heart (controlled negative pressure), a
benefit that is rarely discussed. We run a pressure isola-
tor from the venous line that is connected to an elec-
trical pressure monitor on the heart lung machine. This
monitoring provides us with a digital readout of the
pressure in the venous line. Accurately monitoring and
controlling this quality indicator facilitates optimisation
of the haemodynamic balance between circulating vol-
ume, cardiac output (arterial pump flow) and SVR.
i. Venous collapse pressure is patient-specific. It
depends on the patient’s anatomy and cannula size,
but most importantly on the negative pressure
generated by venous drainage. In a pilot study of 20
patients we found the patient-specific venous
collapse pressure varies from -8 mmHg to -54
mmHg. The same study showed that gravity venous
drainage generates a range of -26 mmHg to -48
mmHg and vacuum assisted generates a range of -56
mmHg to -79 mmHg. This collapse pressure varies
from -8 mmHg to -54 mmHg. Gravity venous
drainage generates a range of -26 mmHg to -48
mmHg and vacuum assisted venous drainage
generates a range of -56 mmHg to -79 mmHg.
Given that CPB most commonly utilises gravity
venous drainage (uncontrolled and unmonitored),
the negative pressures generated will exceed the
patient specific collapse pressure for a large group of
patients in our pilot. This pressure magnitude can
cause venous collapse and even though it may not
stop blood drainage to the circuit, the risk of venous
congestion (especially Liver) and resulting sub-optimal end organ perfusion is increased. Vacuum
assisted venous drainage increases this risk further.
The benefits of accurately monitored and controlled
kinetic venous drainage provided by mCPB will
minimise this risk.
ii. The patient-prime interaction is optimised with ante
grade and retrograde autologous priming. This
method mixes the blood and prime away from the
tissues and results in a reduced oncotic
destabilization. As a result mCPB stabilises
haematocrit much quicker, whereas the initial prime
load for cCPB requires several passes through the
circuit to stabilise the haematocrit (Figures 2 and 3).
Ti et al. [9] reported cardiac index targets were diffi-
cult to achieve using mCPB. This can happen if the
management of the technology is not considered,
resulting in volume restrictive strategy focusing on
maintaining haematocrit only. Our philosophy is to shift
attention to the human management aspect of the tech-
nology, optimising patient-volume interaction, haemato-
crit, arterial flow and circulating volume without being
volume restrictive. The mCPB closed system allows bet-
ter informed haemodynamic balance management.
Figure 2A shows the benefit in haematocrit manage-
ment of gradual and pre-emptive volume addition,
with the volume determined by the patient’s require-
ment. A low haematocrit does not entail a failure of
the technology if the hemodynamic balance is man-
aged accurately and the patient requires volume, all
the other advantages outlined still remain. Neverthe-
less, there is no doubt that mCPB places greater
demands on the perfusionist, as it requires active, in-
formed management throughout the operation in
order to integrate optimally drug/fluid addition, blood
suction, vent and SVR management.
Figure 2 Haematocrit stabilisation mCPB vs. cCPB. Graphs are illustrative only; each panel is based on data for a randomly selected individual
per technique: Volume Management.
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lected, with no exclusions due to the technical complex-
ity of the operation. Table 4 describes the patient’s
preoperative, operative and postoperative characteristics.
Less than 9% of patients had red blood cells transfused,
and less than 5% of patients required platelets or fresh
frozen plasma. The frequencies of post-operative com-
plications were unremarkable given the nature of the co-
hort. No technical problems related to the use of the
mCPB were reported throughout the all series.
Discussion
Miniaturised CPB should be viewed as a delicate balance
between benefit (for the patient and publicly fundedFigure 3 Haematocrit stabilisation mCPB vs. cCPB. Graphs are illustrativ
per technique: Patient/Prime Interaction.health services), intra-operative safety margins and clin-
ical applicability rather than as a strategy to minimize
the circuit without clear objectives. A common sense
and informed approach needs to be applied when con-
sidering what to minimise; For example, switching from
a 1.8 m2 to a 1.1 m2 oxygenator (where the latter is more
efficient in terms of gas exchange) when compared to a
more common strategy used by perfusion teams to limit
FSA, it equates to 42 m of 3/8” tubing. Our choice of
oxygenator facilitates a substantial reduction in FSA with
an acceptable safety margin and 4.5 litre flow per minute
as compared to a traditional Avant Sorin oxygenator
which has 1.8 m2 FSA with an inefficient use of fibre
bundles despite a relatively higher safety margin.e only; each panel is based on data for a randomly selected individual
Table 4 Pre, intra and post-operative characteristics (n = 184)
Patient data Mini CPB (n. =180)
n %
Male 130 70.7
Euro score (logistic) 8.4 (±9.9)
Previous myocardial infarction 44 23.9
Diabetes 58 31.5
Hypertension 155 84.2
Preoperative renal disease Creatinine >200 umol/l 13 7.1
Creatinine >200 umol/l and dialysis 2 1.1
Dialysis for CRF >6 weeks prior to surgery 3 1.6
Extent of coronary disease One vessel 15 8.2
Two vessels 20 10.9
Three vessels 63 34.2
Ejection fraction category Fair (LVEF 30-49%) 24 13.0
Poor (LVEF <30%) 17 9.2
Cross-clamp time, (minutes) 42.9 (±29.5)
CPB time, minutes 71.0 (± 41.9)
Intra-aortic balloon pump 4 2.2
Blood product usage PRC 8 4.3
PRC ,FFP, platelets 5 2.7
Total chest tube drainage (ml) 801 (±483)
Reoperation for bleeding 2 1.1
Renal Complications 3 1.6
Stroke 1 0.5
In hospital death (30 days) 2 1.1
CRF Chronic Renal Failure, LVEF Left Ventricular Ejection Fraction, CPB Cardiopulmonary Bypass, FFP Fresh Frozen Plasma.
Mean and standard deviation.
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creased technical knowledge of the cardiac team. With
such involvement, mCPB enhances monitoring and con-
sequently reduces introduction of air from sample lines,
ports, the surgical field and additions of fluid. It also
brings to the attention of the perfusionist poor vent and
suction management, encourages good multidisciplinary
communication, and promotes continuous monitoring
of SVR and hemodynamic balance. Highlighting sub-
optimal CPB management improves quality. Emphasising
the introduction of air from sample ports and fluid addi-
tions lead to a decrease in air emboli and may reduce the
risk of a neurological complication. Venting is important
to provide a bloodless field with optimal vision; it should
be balanced with the resultant damage caused to the
blood constituents. mCPB promotes optimisation of this
balance. All pericardial suction blood is processed via cell
saving technology.
Before undertaking more complex cases with mCPB,
perfusionists should acquire the skill set to managemCPB in low risk circumstances because it takes time to
learn to manage mCPB technology to maximise its bene-
fits. However, we believe the greatest benefits of mCPB
may arise for more complex operations and higher risk
patient populations with significant co-morbidity. Des-
pite evidence that mCPB has important clinical benefits
[6] it has not been widely implemented, probably be-
cause previous RCTs evaluated diverse systems several
of which had limited clinical applicability to usual care.
After initial development of our mCPB technique and
implementation in usual care by one surgeon, it is now
progressively adopted by the rest of the departmental
surgeons.
Conclusion
The Hammersmith mCPB is a “next generation” system
which uses standard commercially available components.
It aims to maintain safety margin and the benefit of
miniaturised system whilst reducing the human factor
demands.
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